# Clinical Cases: Hepatobiliary Anatomy and Physiology ## Case 1: Jaundice - Distinguishing Causes ### Patient Presentation **Demographics:** 55-year-old male **Chief Complaint:** Yellow skin and eyes for 2 weeks with dark urine and pale stools **History of Present Illness:** The patient noticed progressive yellowing of his eyes and skin over the past 2 weeks. His urine has become dark "like tea," and his stools have become pale and clay-colored. He has generalized itching, worse at night. He denies abdominal pain but reports a 10-pound weight loss over 2 months with decreased appetite. **Past Medical History:** Type 2 diabetes, new diagnosis 6 months ago (unintentional) **Social History:** Never smoked, social alcohol (1-2 drinks/week) ### Physical Examination - **Vital Signs:** Normal - **General:** Jaundiced male, appears uncomfortable from pruritus - **HEENT:** Icteric sclerae - **Abdomen:** Non-tender, no hepatomegaly; palpable, non-tender gallbladder (Courvoisier's sign positive) - **Skin:** Jaundice, excoriations from scratching ### Workup and Results - **Liver Function Tests:** Total bilirubin 14.2 mg/dL, direct bilirubin 11.8 mg/dL (conjugated hyperbilirubinemia), ALP 485 U/L (markedly elevated), GGT 320 U/L, AST 68 U/L, ALT 72 U/L - **CBC:** Normal - **Abdominal Ultrasound:** Dilated intrahepatic and extrahepatic bile ducts (CBD 14 mm); no gallstones; pancreatic head mass visualized - **CT Abdomen with Pancreas Protocol:** 3.5 cm mass in pancreatic head; dilated bile duct and pancreatic duct ("double duct sign"); liver metastases present ![Obstructive Jaundice Double Duct Sign](case_01_image.jpg) *CT scan demonstrating the "double duct sign" - simultaneous dilation of both the common bile duct and pancreatic duct (arrows) - highly suggestive of pancreatic head malignancy causing obstruction.* **Image Source:** Case courtesy of Radiopaedia.org ### Diagnosis **Obstructive (Posthepatic) Jaundice Secondary to Pancreatic Head Adenocarcinoma** ### Clinical Correlation to Hepatobiliary Physiology Bilirubin, the end product of heme degradation, is transported to the liver bound to albumin, where hepatocytes take it up, conjugate it with glucuronic acid (making it water-soluble), and excrete it into bile canaliculi. In posthepatic (obstructive) jaundice, conjugated bilirubin cannot be excreted into the duodenum. The cholestatic pattern (markedly elevated ALP and GGT with modest transaminase elevation) indicates bile duct obstruction. Dark urine occurs because water-soluble conjugated bilirubin is renally excreted. Pale stools result from absence of bilirubin reaching the intestine (no urobilinogen formed). Pruritus is caused by bile salt deposition in skin. Courvoisier's sign (palpable, non-tender gallbladder) suggests malignant obstruction, as chronically diseased gallbladders (from stones) do not distend. ### Treatment - ERCP with biliary stent placement for symptomatic relief of jaundice - Given metastatic disease: palliative chemotherapy (FOLFIRINOX or gemcitabine/nab-paclitaxel) - Symptom management: cholestyramine for pruritus - Palliative care consultation --- ## Case 2: Esophageal Varices and Portal Hypertension ### Patient Presentation **Demographics:** 52-year-old male **Chief Complaint:** Large-volume hematemesis **History of Present Illness:** The patient vomited approximately 500 mL of bright red blood 2 hours ago followed by a second episode en route to the hospital. He has known history of alcohol-related cirrhosis but has continued drinking. He notes increasing abdominal girth over the past 2 months and has required increasing doses of diuretics for his "fluid problem." **Past Medical History:** Alcoholic cirrhosis diagnosed 3 years ago, portal hypertensive ascites, thrombocytopenia **Social History:** Heavy alcohol use (8-10 beers daily for 30 years) ### Physical Examination - **Vital Signs:** BP 88/52 mmHg, HR 128 bpm, Temperature 36.8C - **General:** Pale, diaphoretic male in distress - **HEENT:** Icteric sclerae - **Cardiovascular:** Tachycardic, weak peripheral pulses - **Abdomen:** Distended with shifting dullness (ascites), caput medusae visible, splenomegaly - **Extremities:** Palmar erythema, spider angiomata on chest - **Neurologic:** Oriented but slow to respond, asterixis present ### Workup and Results - **CBC:** Hemoglobin 7.2 g/dL, Platelets 68,000 - **INR:** 2.1 - **BMP:** Cr 1.8 mg/dL - **Albumin:** 2.4 g/dL - **Child-Pugh Score:** 11 (Class C) - **MELD Score:** 24 - **Upper Endoscopy (after resuscitation):** Three columns of large esophageal varices with red wale signs; active bleeding from one varix; gastric varices present ![Esophageal Varices Endoscopy](case_02_image.jpg) *Endoscopic image of large esophageal varices with prominent red wale signs (longitudinal red streaks) indicating high risk of bleeding. These portosystemic collaterals form due to portal hypertension redirecting blood flow.* **Image Source:** Wikimedia Commons, CC BY-SA 3.0 ### Diagnosis **Acute Variceal Hemorrhage in Decompensated Cirrhosis** ### Clinical Correlation to Hepatobiliary Anatomy/Physiology Portal hypertension develops when intrahepatic vascular resistance increases due to cirrhotic architectural distortion. Normal hepatic venous pressure gradient (HVPG) is <5 mmHg; varices form when HVPG exceeds 10 mmHg. The portal vein normally carries nutrient-rich blood from the GI tract to the liver. In portal hypertension, blood is diverted through portosystemic collaterals at sites where the portal and systemic venous systems communicate. Esophageal varices form at the gastroesophageal junction where the left gastric (coronary) vein connects to esophageal veins draining into the azygos system. Other collaterals include caput medusae (paraumbilical veins), hemorrhoids (inferior rectal veins), and splenorenal shunts. The liver's synthetic dysfunction (low albumin, elevated INR) reflects lost hepatocyte mass. ### Treatment - Resuscitation: Two large-bore IVs, crystalloid, restrictive transfusion (target Hgb 7-8 g/dL) - Vasoactive therapy: Octreotide 50 mcg bolus, then 50 mcg/hr infusion (reduces portal pressure) - Prophylactic antibiotics: Ceftriaxone 1g IV daily (reduces mortality) - Urgent endoscopy with band ligation of varices - PPI therapy after banding - Consider early TIPS (within 72 hours) given high-risk features - Secondary prophylaxis: Repeat banding until eradication + non-selective beta-blocker - Alcohol cessation counseling; liver transplant evaluation --- ## Case 3: Gilbert Syndrome ### Patient Presentation **Demographics:** 22-year-old male college student **Chief Complaint:** Intermittent yellow eyes noticed by friends **History of Present Illness:** The patient's roommates have commented that his eyes "look yellow" occasionally, particularly during finals week or when he has been sick. He reports no abdominal pain, change in stool color, or dark urine. He feels well between episodes. He recently had a viral upper respiratory infection and noticed his eyes became more yellow. **Past Medical History:** Mononucleosis 2 years ago (recovered without complications) **Family History:** Father has "the same thing" with occasional yellow eyes **Social History:** College student, occasional alcohol at parties, no medications, no supplements ### Physical Examination - **Vital Signs:** Normal - **General:** Healthy-appearing young male with mild scleral icterus - **Abdomen:** Soft, non-tender, no hepatomegaly, no splenomegaly - **Skin:** Faint jaundice, no pruritus marks ### Workup and Results - **Liver Function Tests:** Total bilirubin 3.8 mg/dL, indirect (unconjugated) bilirubin 3.4 mg/dL, direct bilirubin 0.4 mg/dL; AST 22 U/L, ALT 25 U/L, ALP 68 U/L (all normal) - **CBC:** Hemoglobin 14.8 g/dL, reticulocyte count normal (rules out hemolysis) - **Haptoglobin:** Normal - **LDH:** Normal - **Fasting Bilirubin (48-hour fast provocation):** Rose to 5.2 mg/dL (characteristic increase with fasting) ![Gilbert Syndrome Mechanism](case_03_image.jpg) *Diagram illustrating bilirubin metabolism in Gilbert syndrome, showing reduced activity of UGT1A1 enzyme leading to unconjugated hyperbilirubinemia without liver disease or hemolysis.* **Image Source:** Adapted from educational materials ### Diagnosis **Gilbert Syndrome** ### Clinical Correlation to Bilirubin Metabolism Gilbert syndrome is a benign condition affecting 5-10% of the population, caused by reduced activity of UDP-glucuronosyltransferase 1A1 (UGT1A1), the hepatocyte enzyme that conjugates bilirubin with glucuronic acid. A promoter region polymorphism (TA repeat) in the UGT1A1 gene reduces expression to approximately 30% of normal. This is sufficient for normal bilirubin handling under basal conditions but becomes limiting during physiologic stress (fasting, illness, exercise). The unconjugated hyperbilirubinemia is harmless because bilirubin levels rarely exceed 5 mg/dL, far below neurotoxic thresholds. The normal aminotransferases and alkaline phosphatase exclude liver disease. The absence of hemolysis markers (normal reticulocytes, LDH, haptoglobin) excludes prehepatic causes. ### Treatment - No treatment required - this is a benign condition - Reassurance and education: episodes are expected during stress, illness, or fasting - Avoid prolonged fasting - Genetic counseling not typically needed (benign condition) - Note in medical record to avoid unnecessary workup in future - Relevant for drug metabolism: reduced UGT1A1 affects clearance of some drugs (e.g., irinotecan toxicity risk)